Brian Ting M.D.

Director of Gastroenterology and Hepatology Research, Tulane University School of Medicine, Assistant Professor of Clinical Medicine

Tulane Cancer Center Member - Translational Oncology Research Program, Gastroenterology Clinical Trials Unit Director
School of Medicine
Medicine Gastroenterology
Dr. Ting_ Hepatologist

Education & Affiliations

Medical School – National Taiwan University (NTU) College of Medicine, Taipei, Taiwan – 2014
Residency – Internal Medicine, Johns Hopkins Hospital, Baltimore, MD – 2019
Fellowship – Gastroenterology, Johns Hopkins Hospital, Baltimore, MD – 2021
Advanced Fellowship – Transplant Hepatology – Chief Fellow, Johns Hopkins Hospital, Baltimore, MD – 2022

Areas of Expertise

Hepatology
Liver Transplantation
Gastroenterology

Biography

Dr. Ting graduated from National Taiwan University and trained at Johns Hopkins School of Medicine for internal medicine residency, gastroenterology, and transplant hepatology fellowship before joining Tulane University School of Medicine as a transplant hepatology faculty.  He is engaged in conducting translational research with alcohol associated liver disease, metabolic dysfunction associated liver disease, nutrition, artificial intelligence, transplant organ utilization, in addition to his roles as site PI of industry sponsored clinical trials and coinvestigator in federally sponsored studies.  

 

 

Contributions

RESEARCH ACTIVITIES
Original Research [OR]

1. Ting PS, Chen L, Yang WC, Huang TS, Wu CC, Chen YY. Gender and age disparity in the initiation of life-supporting treatments: a population-based cohort study. BMC Med Ethics. 2017 Nov 15;18(1):62.

2. Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis. 2019 Dec;21(6): e13194.

3. Chen PH, Ting PS, Almazan E, Chander G, Cameron A, Gurakar A. Inter-Hospital Escalation-of-Care Referrals for Severe Alcohol-Related Liver Disease with Recent Drinking During the COVID-19 Pandemic. Alcohol Alcohol. 2022 Mar 12;57(2):185-189. PMID: 34219147

4. Yeo YH, He X, Ting PS, Zu J, Almario CV, Spiegel BM, Ji F. Evaluation of Trends in Alcohol Use Disorder-Related Mortality in the US Before and During the COVID-19 Pandemic. JAMA Netw Open. 2022 May 2;5(5):e2210259. PMID: 35507347 

5. Krishnan A, Prichett L, Liu Y, Ting PS, Alqahtani SA, Kim AK, Ma M, Hamilton JP, Woreta TA, Chen PH. Risk of Severe Illness and Risk Factors of Outcomes of COVID-19 in Hospitalized Patients with Chronic Liver Disease in a Major U. S. Hospital Network. Can J Gastroenterol Hepatol. 2022 Nov 3;2022:8407990. PMID: 36387036

6. Yeo YH, Samaan JS, Ng WH, Ting PS, Trivedi H, Vipani A, Ayoub W, Yang JD, Liran O, Spiegel B, Kuo A. Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma. Clin Mol Hepatol. 2023 Mar 22. doi: 10.3350/cmh.2023.0089. PMID: 36946005

7. Samaan JS, Yeo YH, Ng WH, Ting PS, Trivedi H, Vipani A, Yang JD, Liran O, Spiegel B, Kuo A, Ayoub W. ChatGPT's ability to comprehend and answer cirrhosis related questions in Arabic. Arab J Gastroenterol. 2023 Sep 4;S1687-1979(23)00058-8. doi: 10.1016/j.ajg.2023.08.001. PMID: 37673708

8. Mony S, Hu B, Joseph A, Aihara H, Ferri L, Bhatt A, Mehta A, Ting B, Chen A, Kalra A, Farha J, Onimaru M, Wang A, He L, Luo Q, Inoue H, Ngamruengphong S. CLINICAL OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL NEOPLASIA IN CLOSE PROXIMITY TO ESOPHAGEAL VARICES: A MULTICENTER INTERNATIONAL EXPERIENCE. Endoscopy. 2023 Aug 23. doi: 10.1055/a-2159-2557. PMID: 37611620

9. Tseng TS, Lin WT, Ting PS, Huang CK, Chen PH, Gonzalez GV, Lin HY. Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Nutrients. 2023 Sep 15;15(18):3997. doi: 10.3390/nu15183997. PMID: 37764782

10. Ting PS, Lin WT, Huang CK, Lin HY, Tseng TS, Chen PH. Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease. Alcohol Clin Exp Res. 2023;00:1–10. DOI: 10.1111/acer.15220. PMID: 38206286

11. Ting PS, Lin WT, Liangpunsakul S, Novack M, Huang CK, Lin HY, Tseng TS, Chen PH. Convergence of Alcohol Consumption and Dietary Quality in US Adults Who Currently Drink Alcohol: An Analysis of Two Core Risk Factors of Liver Disease. Nutrients. 2024 Nov 13;16(22):3866. doi: 10.3390/nu16223866. PMID: 39599652

12. Chen H, Nisar MA, Mulla J, Li X, Cao K, Lu S, Nagaoka K, Wu S, Ting PS, Tseng TS, Lin HY, Yin XM, Feng W, Wu Z, Cheng Z, Mueller W, Bay A, Schechner L, Bai X, Huang CK. Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease. EMBO Mol Med. 2025 Mar 31. doi: 10.1038/s44321-025-00224-4. PMID: 40164757

Clinical Trials - Active

1. Site PI for CymaBay 31731 ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) at Tulane East Jefferson General Hospital

2. Site PI for CymaBay 32251 IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) at Tulane East Jefferson General Hospital

3. Site PI for CymaBay 41837 AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis at Tulane East Jefferson General Hospital

Clinical Trials – Past/Closed

1. Site PI for Bristol-Myers Squibb (BMS) – CA209-9DX Study for Adjuvant Nivolumab After Curative Hepatocellular Carcinoma (HCC) Resection at Tulane University Medical Center

2. Site PI for Viking VK2809-202 A Phase 2B, Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Months Followed by a 4 Week Off-drug Phase in Subjects with NASH at Tulane University Medical Center

3. Site Principal Investigator (PI) for Gilead GS-US-454-6075 A Phase 2, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis at Tulane University Medical Center

4. Site PI for Madrigal/SCLRC MGL-3196-11 A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation at Tulane University Medical Center

Case Reports [CR]

1. Bishehsari F, Ting PS, Green RM. Recurrent gastrointestinal bleeding and hepatic infarction after liver biopsy. World J Gastroenterol. 2014 Feb 21;20(7):1878-81.

2. Ting PS, Agarwalla A, Woreta TA. A Mimic of Hepatic Encephalopathy: Two Cases of Cryptococcal Meningitis in North America. J Clin Transl Hepatol. 2019 Jun 28;7(2):191-193.

Book Chapters, Monographs [BC]

1. Abu S, Ting PS, Chen PH. In: Evidence-Based Gastrointestinal Nutrition: A Clinician’s Handbook. Accepted for publication in 2020. Chapter 25: Liver Transplant.

Books, Textbooks [BK]

1. Chiou HY, Ting PS, Chen TJ, Chuang SW, Hsu YH, Sheu ML, Tang CH, Tsai FJ, Yang CM. Universal Health Insurance – Lessons Learned From Taiwan. 2016. Taipei, Taiwan: Taipei Medical University.

Media Releases or Interviews [MR]

1. Interview for the Clinical Liver Disease journal regarding the publication: Behavioral Treatment for Patients With Alcohol-Related Liver Disease: A Primer for Hepatologists. Feb 25, 2020. Accessible by: https://aasldpubs.onlinelibrary.wiley.com/hub/journal/20462484/video/15-1-interview-ting

2. Interview for NOLA.com for the article “Louisiana doctors link dietary supplements to liver injuries, failure. Here's what to know.” On Aug 13, 2024. Accessible by: https://www.nola.com/entertainment_life/louisiana_health/louisiana-health-supplements-wellness/article_dd7eeb84-5349-11ef-90a8-6fc64a393b56.html

3. Interview for The New York Times for the article “Is There a Least Bad Alcohol?” on Jun 6, 2025. Accessible by: https://www.nytimes.com/2025/05/20/well/eat/health-effects-of-alcohol-wine-beer-liquor.html

4. Interview for Healio for the article “Cessation therapy for alcohol use disorder ‘clearly underutilized,’ data show” on Jun 17, 2025. Accessible by: https://www.healio.com/news/gastroenterology/20250616/cessation-therapy-for-alcohol-use-disorder-clearly-underutilized-data-show

Publications

Review Articles [RA]

1. Limketkai BN, Hendler S, Ting PS, Parian AM. Fecal Microbiota Transplantation for the Critically Ill Patient. Nutr Clin Pract. 2019 Feb;34(1):73-79.

2. Ting PS, Wheatley J, Chen PH. Behavioral Treatment for Patients With Alcohol-Related Liver Disease: A Primer for Hepatologists. Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):31-35.

3. Muhammad H, Hammami MB, Muhammad H, Ting PS, Simsek C, Saberi B, Gurakar A. Can HCV Viremic Organs Be Used in Liver Transplantation to HCV Negative Recipients? OBM Hepatology and Gastroenterology 2020;4(2):8; doi:10.21926/obm.hg.2002046.


4. Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol. 2021 Mar 27;13(3):291-299. PMID: 33815673


5. Ting PS, Gurakar A, Wheatley J, Chander G, Cameron AM, Chen PH. Approaching Alcohol Use Disorder after Liver Transplantation for Acute Alcoholic Hepatitis. Clin Liver Dis. 2021 May 26:25(3). PMID: 34229846


6. Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol. 2021 Oct 28;9(5):738-748. PMID: 34722189


7. Muhammad H, Zaffar D, Tehreem A, Ting PS, Simsek C, Turan I, Alqahtani S, Saberi B, Gurakar A. An Update on Usage of High-Risk Donors in Liver Transplantation. J Clin Med. 2021 Dec 31;11(1):215. PMID: 35011956


8. Muhammad H, Gurakar M, Ting PS, Alsughayer AM, Luu H, Zaffar D, Alqahtani S, Bonder A, Gurakar A, Saberi B. Long-Term Outcomes of Living Donor Versus Deceased Donor Liver Transplant for Hepatocellular Carcinoma in the United States. Exp Clin Transplant. 2022 Mar;20(3):279-284. PMID: 35352634